PENS syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:313936Q82.5
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

PENS syndrome stands for Pigmentation defects, Eczema, Nail dystrophy, and Sensorineural deafness. It is an extremely rare genetic condition that affects multiple body systems, most notably the skin, nails, and hearing. People with PENS syndrome typically develop patchy or abnormal skin coloring (pigmentation changes), chronic eczema (itchy, inflamed skin), problems with the nails such as thickening, ridging, or brittleness, and hearing loss caused by damage to the inner ear nerves (sensorineural hearing loss). The condition is classified under congenital non-neoplastic nevi and other skin malformations. Because PENS syndrome is so rare, the medical understanding of this condition is still limited. Symptoms usually appear early in life, and the combination of skin, nail, and hearing problems together is what helps doctors recognize this specific syndrome. There is currently no cure for PENS syndrome. Treatment focuses on managing each symptom individually — for example, using moisturizers and anti-inflammatory creams for eczema, hearing aids or cochlear implants for hearing loss, and nail care for dystrophic nails. A team of specialists is typically needed to provide comprehensive care. Research into the genetic basis and potential targeted treatments is ongoing but limited due to the rarity of the condition.

Also known as:

Key symptoms:

Patchy or uneven skin coloringChronic eczema or itchy, inflamed skinBrittle, thickened, or ridged nailsHearing loss present from early lifeDry skinSkin rashesNail discolorationSensitivity to skin irritants

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Oct 2025Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

Rhode Island Hospital — NA

TrialRECRUITING
Sep 2025Predictive Model for PENS Response in Subacromial Pain Syndrome

Néstor Requejo Salinas — NA

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for PENS syndrome.

View clinical trials →

No actively recruiting trials found for PENS syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the PENS syndrome community →

No specialists are currently listed for PENS syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to PENS syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open PENS syndromeForum →

No community posts yet. Be the first to share your experience with PENS syndrome.

Start the conversation →

Latest news about PENS syndrome

Disease timeline:

New recruiting trial: Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

A new clinical trial is recruiting patients for PENS syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the best skin care routine to manage my child's eczema?,How severe is the hearing loss, and what type of hearing device would be most helpful?,Should we pursue genetic testing, and what would the results mean for our family?,Are there any clinical trials or new treatments being studied for this condition?,What specialists should we see regularly, and how often?,How can we support speech and language development given the hearing loss?,Is there a risk that siblings or future children could also have this condition?

Common questions about PENS syndrome

What is PENS syndrome?

PENS syndrome stands for Pigmentation defects, Eczema, Nail dystrophy, and Sensorineural deafness. It is an extremely rare genetic condition that affects multiple body systems, most notably the skin, nails, and hearing. People with PENS syndrome typically develop patchy or abnormal skin coloring (pigmentation changes), chronic eczema (itchy, inflamed skin), problems with the nails such as thickening, ridging, or brittleness, and hearing loss caused by damage to the inner ear nerves (sensorineural hearing loss). The condition is classified under congenital non-neoplastic nevi and other skin mal

How is PENS syndrome inherited?

PENS syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does PENS syndrome typically begin?

Typical onset of PENS syndrome is infantile. Age of onset can vary across affected individuals.